Product Description: Odronextamab is a hinge-stabilised, fully human IgG4-based CD20 × CD3 bispecific antibody that binds CD3 on T cells and CD20 on B cells[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Rajat Bannerji, et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet H
CAS Number: 1801338-64-6
Molecular Weight: N/A
Compound Purity: 99.50
Research Area: Cancer; Inflammation/Immunology
Solubility: H2O
Target: CD20